# Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.

> PubMed lists PMID 38247052 in The Annals of pharmacotherapy as Review, Letter, with publication-date metadata of 2024-01-21 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38247052-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38247052-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-38247052-tirzepatide-v1.json
- Content SHA-256: `6d71b7b8544555e2253cb082029f2b7ad4f2334955e6080e38f8e4a9e1e7ae19`

## Claims and source pins

### Headline

Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. ([`pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db`](#source-pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db))

### Summary

PubMed lists PMID 38247052 in The Annals of pharmacotherapy as Review, Letter, with publication-date metadata of 2024-01-21 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db`](#source-pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db))

### Paragraph 1

PubMed lists PMID 38247052 in The Annals of pharmacotherapy as Review, Letter, with publication-date metadata of 2024-01-21 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db`](#source-pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db`](#source-pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db))

## Sources

<a id="source-pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db"></a>
- **Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. · retained source version 1:2026-07-06:current:0be4c46fb1db5dd7a823239f52996064b0f0e5eb4c465d7a56b8e7eacf80a4db** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38247052/) (`pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-38247052-tirzepatide-v1.json SHA-256: 6d71b7b8544555e2253cb082029f2b7ad4f2334955e6080e38f8e4a9e1e7ae19.